Search
khorana risk score
Indications:
- risk assessment of chemotherapy-associated thrombosis
- predicts risk of venous thromboembolism for cancer patients depending on type of cancer & other factors
- for use in patients with solid tumors & lymphoma
Contraindications:
- not for use in patients with brain tumors or multiple myeloma
Procedure:
- 5 predictive per-chemotherapy variables:
- site of cancer
- 2 points for very high-risk site: stomach cancer. pancreatic cancer
- 1 point for high-risk site: lung cancer, lymphoma, urogenital cancer
- platelet count >= 350 x 10(9)/L (1 point)
- blood hemoglobin < 10 g/dL &/or use of erythropoiesis-stimulating agents (1 point)
- leukocyte count > 11 x 10(9)/L (1 point)
- body mass index of >=35 kg/m(2) (1 point)
General
numerical rating scale (NRS)
References
- Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW.
Development and validation of a predictive model for chemotherapy-associated thrombosis.
Blood 2008 May 15, 111 (10): 4902-7
PMID: 18216292 PMCID: PMC2384124 Free PMC article
- Mulder FI, Candeloro M, Kamphuisen PW et al
The Khorana score for prediction of venous thromboembolism in cancer patients:
a systematic review and meta-analysis
Haematologica. 2019 Jun;104(6):1277-1287.
PMID: 30606788 PMCID: PMC6545838 Free reference
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545838/
- Khorana Risk Score for Venous Thromboembolism in Cancer Patients.
https://www.mdcalc.com/khorana-risk-score-venous-thromboembolism-cancer-patients